Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 3 2Phase 2 2Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Prostatic Neoplasms 3Prostate Cancer Metastatic 2Myasthenia Gravis 2Multiple Myeloma 2Waldenstrom Macroglobulinemia 1Subcutaneous panniculitis-like T-cell lymphoma 1Skin Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Pneumonia 1Pituitary Neoplasms 1Neoplasms, Plasma Cell 1Neoplasm, Residual 1Metastatic Castration-resistant Prostate Cancer 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lung Neoplasms 1Lung Diseases, Interstitial 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1Dementia 1Craniopharyngioma 1Cognitive Dysfunction 1Autoimmune Diseases 1Arthritis, Rheumatoid 1Adrenal Insufficiency 1

Interventions

Prednisone 2enzalutamide 1cabazitaxel 1Prednisolone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Prostate Cancer Metastatic × Prednisone × Clear all
NCT02485691 2022-05-27

CARD

Sanofi

Phase 4 Completed
255 enrolled 21 charts
Genitourinary

Prostate Cancer Metastatic

NCT02074137 2016-06-02

Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer

Sanofi

Phase 4 Completed
10 enrolled
Genitourinary

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡